Opinion
BioSpaceOpinion

Opinion: The GLP-1 Paradox—Why Is a $95B Obesity Market Ignoring Its Biggest Problem?

The nausea and other gastrointestinal side effects of weight loss drugs like Novo Nordisk’s Wegovy or Eli Lilly’s Zepbound will limit how much these drugs can help patients and stunt the overall ...

Thinking about GLP-1 for weight loss? Here’s the full scoop

This article was reviewed by Darragh O’Carroll, MD. GLP-1 for Weight Loss: Everything You Need to Know Key takeaways: GLP-1s ...

After the FDA crackdown, here’s how some companies are still selling GLP-1s

A new ‘microdosing’ trend lets pharmacies offer compounded versions of GLP-1 drugs even after the Food and Drug ...

Price cuts help more Americans start weight-loss drugs but maybe not stay on them

A Trump administration deal to cut prices for popular weight-loss drugs like Wegovy and Zepbound will allow millions more ...

Diabetes meds for weight loss, explained by the pros

This article was reviewed by Darragh O’Carroll, MD. Diabetes Medications for Weight Loss: What to Know Key takeaways: Some ...

What Is GLP-1 Microdosing and Does It Lead to Weight Loss? Doctors Explain

People are trying mini doses of GLP-1 drugs to lose weight or maintain weight loss, but doctors urge caution, calling the ...
Medindia

Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans

Eli Lilly and Company (NYSE: LLY) today announced an agreement with the U.S. government to expand access to its obesity medicines and re ...

Lower prices mean more Americans can start weight-loss drugs, doctors say

A Trump administration deal to cut prices for popular weight-loss drugs like Wegovy and Zepbound will allow millions more ...
WESH

Major insurance changes are coming for weight loss drugs. Here’s how it could affect patients

Last week, Tara Eacobacci had an appointment with her doctor that was devoted exclusively to the topic of health insurance. A major change to her prescription benefits meant the medication she was ...